AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET
AB SCIENCE WILL HOST A LIVE WEBCAST ON ITS MICROTUBULE DESTABILIZER AGENTS (MDA) PLATFORM ON THURSDAY MARCH 16, 2023, FROM 6PM TO 7PM CET
Paris, 15 March, 2023, 6pm CET
AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform.
This live webcast will provide further details on:
The pharmacological properties of AB8939 and its key differentiating factors
The therapeutic potential of AB8939, demonstrated through a series of preclinical experiments
The ongoing Phase 1/2 study and the first case report from the initial stage of this study
The following attendees will participate to the live webcast:
Alain Moussy, co-founder and CEO of AB Science
Olivier Hermine, MD, PhD, Head of the hematological department at the Necker-Enfants Malades hospital, Paris, France
Christian Auclair, PhD, expert in onco-pharmacology
Laurent Gros, PhD, Head of Drug Discovery of AB Science
The presentation will be followed by a Q&A session with the management of AB Science.
Dial-In & Webcast Information
Webcast date: Thursday, March 16, 2023. US: 1pm-2pm ET; Europe: 6pm-7pm CET
Dial in numbers to listen the live webcast:
Dial in number for the US: +1 646 722 4916
Dial in number for France: +33 1 72 72 74 03
Dial in number for countries outside US and France: Numbers for other countries are listed on the webcast page
Conference ID: 42846282#
Access to the presentation: Access link to the presentation here
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
Forward-looking Statements - AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.
These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.
For additional information, please contact:
Financial Communication & Media Relations